Cardiovascular effects and safety of intravenous and intramuscular pentamidine isethionate

D. L. Mallory, J. E. Parrillo, Kent R Bailey, G. L. Akin, M. Brenner, H. C. Lane, A. S. Fauci, H. Masur

Research output: Contribution to journalArticle

19 Citations (Scopus)

Abstract

Intramuscular (im) pentamidine isethionate can cause substantial local pain and inflammation at the injection site. This drug is being used more frequently in recent years to treat Pneumocystis pneumonia, particularly in patients with acquired immunodeficiency syndrome. Clinicians began administering it iv despite warnings that iv administration might cause severe hypotension. We investigated the safety of im and iv pentamidine, monitoring hemodynamics after each dose in 11 patients with intra-arterial lines. Results showed only a small (but statistically significant) fall in mean arterial pressure after both im and slow (60 min) iv administration. A concomitant decrease in pulse occurred, but no change in cardiac output, pulmonary capillary occlusion pressure or systemic vascular resistance was noted. These results suggest that it may be safe to infuse pentamidine slowly intravenously. This route is more comfortable to patients than im administration.

Original languageEnglish (US)
Pages (from-to)503-505
Number of pages3
JournalCritical Care Medicine
Volume15
Issue number5
StatePublished - 1987
Externally publishedYes

Fingerprint

Pentamidine
Safety
Vascular Access Devices
Pneumocystis Pneumonia
Cardiac Output
Vascular Resistance
Hypotension
Pulse
Arterial Pressure
Acquired Immunodeficiency Syndrome
Hemodynamics
Inflammation
Pressure
Pain
Lung
Injections
Pharmaceutical Preparations

ASJC Scopus subject areas

  • Critical Care and Intensive Care Medicine

Cite this

Mallory, D. L., Parrillo, J. E., Bailey, K. R., Akin, G. L., Brenner, M., Lane, H. C., ... Masur, H. (1987). Cardiovascular effects and safety of intravenous and intramuscular pentamidine isethionate. Critical Care Medicine, 15(5), 503-505.

Cardiovascular effects and safety of intravenous and intramuscular pentamidine isethionate. / Mallory, D. L.; Parrillo, J. E.; Bailey, Kent R; Akin, G. L.; Brenner, M.; Lane, H. C.; Fauci, A. S.; Masur, H.

In: Critical Care Medicine, Vol. 15, No. 5, 1987, p. 503-505.

Research output: Contribution to journalArticle

Mallory, DL, Parrillo, JE, Bailey, KR, Akin, GL, Brenner, M, Lane, HC, Fauci, AS & Masur, H 1987, 'Cardiovascular effects and safety of intravenous and intramuscular pentamidine isethionate', Critical Care Medicine, vol. 15, no. 5, pp. 503-505.
Mallory DL, Parrillo JE, Bailey KR, Akin GL, Brenner M, Lane HC et al. Cardiovascular effects and safety of intravenous and intramuscular pentamidine isethionate. Critical Care Medicine. 1987;15(5):503-505.
Mallory, D. L. ; Parrillo, J. E. ; Bailey, Kent R ; Akin, G. L. ; Brenner, M. ; Lane, H. C. ; Fauci, A. S. ; Masur, H. / Cardiovascular effects and safety of intravenous and intramuscular pentamidine isethionate. In: Critical Care Medicine. 1987 ; Vol. 15, No. 5. pp. 503-505.
@article{02b1412381b240a5ba776269139ab769,
title = "Cardiovascular effects and safety of intravenous and intramuscular pentamidine isethionate",
abstract = "Intramuscular (im) pentamidine isethionate can cause substantial local pain and inflammation at the injection site. This drug is being used more frequently in recent years to treat Pneumocystis pneumonia, particularly in patients with acquired immunodeficiency syndrome. Clinicians began administering it iv despite warnings that iv administration might cause severe hypotension. We investigated the safety of im and iv pentamidine, monitoring hemodynamics after each dose in 11 patients with intra-arterial lines. Results showed only a small (but statistically significant) fall in mean arterial pressure after both im and slow (60 min) iv administration. A concomitant decrease in pulse occurred, but no change in cardiac output, pulmonary capillary occlusion pressure or systemic vascular resistance was noted. These results suggest that it may be safe to infuse pentamidine slowly intravenously. This route is more comfortable to patients than im administration.",
author = "Mallory, {D. L.} and Parrillo, {J. E.} and Bailey, {Kent R} and Akin, {G. L.} and M. Brenner and Lane, {H. C.} and Fauci, {A. S.} and H. Masur",
year = "1987",
language = "English (US)",
volume = "15",
pages = "503--505",
journal = "Critical Care Medicine",
issn = "0090-3493",
publisher = "Lippincott Williams and Wilkins",
number = "5",

}

TY - JOUR

T1 - Cardiovascular effects and safety of intravenous and intramuscular pentamidine isethionate

AU - Mallory, D. L.

AU - Parrillo, J. E.

AU - Bailey, Kent R

AU - Akin, G. L.

AU - Brenner, M.

AU - Lane, H. C.

AU - Fauci, A. S.

AU - Masur, H.

PY - 1987

Y1 - 1987

N2 - Intramuscular (im) pentamidine isethionate can cause substantial local pain and inflammation at the injection site. This drug is being used more frequently in recent years to treat Pneumocystis pneumonia, particularly in patients with acquired immunodeficiency syndrome. Clinicians began administering it iv despite warnings that iv administration might cause severe hypotension. We investigated the safety of im and iv pentamidine, monitoring hemodynamics after each dose in 11 patients with intra-arterial lines. Results showed only a small (but statistically significant) fall in mean arterial pressure after both im and slow (60 min) iv administration. A concomitant decrease in pulse occurred, but no change in cardiac output, pulmonary capillary occlusion pressure or systemic vascular resistance was noted. These results suggest that it may be safe to infuse pentamidine slowly intravenously. This route is more comfortable to patients than im administration.

AB - Intramuscular (im) pentamidine isethionate can cause substantial local pain and inflammation at the injection site. This drug is being used more frequently in recent years to treat Pneumocystis pneumonia, particularly in patients with acquired immunodeficiency syndrome. Clinicians began administering it iv despite warnings that iv administration might cause severe hypotension. We investigated the safety of im and iv pentamidine, monitoring hemodynamics after each dose in 11 patients with intra-arterial lines. Results showed only a small (but statistically significant) fall in mean arterial pressure after both im and slow (60 min) iv administration. A concomitant decrease in pulse occurred, but no change in cardiac output, pulmonary capillary occlusion pressure or systemic vascular resistance was noted. These results suggest that it may be safe to infuse pentamidine slowly intravenously. This route is more comfortable to patients than im administration.

UR - http://www.scopus.com/inward/record.url?scp=0023213477&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0023213477&partnerID=8YFLogxK

M3 - Article

VL - 15

SP - 503

EP - 505

JO - Critical Care Medicine

JF - Critical Care Medicine

SN - 0090-3493

IS - 5

ER -